Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.